

Iowa Medicaid Drug Utilization Review (DUR) Commission

November 1, 2023

Location: **Virtual Only**

Time: 9:30 a.m. – 1:30 p.m. CT

WebEx Meeting Link:

<https://changehealthcare.webex.com/changehealthcare/j.php?MTID=me757ba0bac8c823e2345503ae97695a0>

Dial In: 1-844-621-3956

Meeting Number: 2538 218 3276

Meeting Password: 3NYztjPWY34

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the August 2, 2023 Meeting Minutes
 - b) August 2023 DUR Recommendation Letter to DHHS
 - c) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
 - a) Iowa Total Care
 - b) Amerigroup
 - c) Fee for Service
 - d) Molina Healthcare
 - e) Comparative Summary
5. Public Comment* ([Complete Speaker Conflict of Interest Disclosure Form](#))
 - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure. Five (5) minute maximum limit.
 - Written – Must submit written comments and a completed conflict of interest disclosure.
 - **All submissions must be received no later than 4:30 p.m. CT October 25, 2023.**
 - Send to info@iadur.org Indicate in email if providing written or verbal comment.
 - Reference complete public comment policy [here](#).
6. Retrospective DUR
 - a) Data Presentation(s)
 - i. Antidepressants in Children
 - ii. Antianxiety/Sedatives in Children

- b) Proposal(s)
 - i. Mood Stabilizers in Children
 - ii. Low Dose Quetiapine
- c) Commission Recommendations for Retrospective DUR Agenda Topics
- 7. Prospective DUR
 - a) Seizure Rescue Treatment, Nasal Spray - Quantity Limit – Second Review
- 8. Break (10 minutes)
- 9. Prior Authorization
 - a) Annual Review of Prior Authorization Criteria
 - b) Odevixibat (Bylvay) - Initial Review
 - c) Oral Constipation Agents – Initial Review
 - d) Oral Immunotherapy – Initial Review
 - e) Vesicular Monoamine Transporter (VMAT) 2 Inhibitors – Initial Review
 - f) Antidepressants – Second Review
 - g) Deucravacitinib (Sotyktu) – Second Review
 - h) Tezepelumab (Tezspire) – Second Review
 - i) Janus Kinase Inhibitors – Second Review
- 10. Miscellaneous
 - a) DUR Digest Vol. 36, No. 1 – Initial Review
- 11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a [conflict of interest disclosure](#). Completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict of interest disclosure form late will have their request to speak denied or will not have their comments shared.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131.

Next Meeting
February 7, 2024
Location: TBD